PT831910E - Terapia de combinacao a base de um antagonista epoxi-esteroidal de aldosterona e um antagonista de angiotensina ii para o tratamento de ataque cardiaco congestivo - Google Patents

Terapia de combinacao a base de um antagonista epoxi-esteroidal de aldosterona e um antagonista de angiotensina ii para o tratamento de ataque cardiaco congestivo

Info

Publication number
PT831910E
PT831910E PT96919170T PT96919170T PT831910E PT 831910 E PT831910 E PT 831910E PT 96919170 T PT96919170 T PT 96919170T PT 96919170 T PT96919170 T PT 96919170T PT 831910 E PT831910 E PT 831910E
Authority
PT
Portugal
Prior art keywords
antagonist
angiotensin
epoxy
treatment
esteroidal
Prior art date
Application number
PT96919170T
Other languages
English (en)
Portuguese (pt)
Inventor
John C Alexander
Joseph R Schuh
Richard J Gorczynski
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of PT831910E publication Critical patent/PT831910E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT96919170T 1995-06-07 1996-06-05 Terapia de combinacao a base de um antagonista epoxi-esteroidal de aldosterona e um antagonista de angiotensina ii para o tratamento de ataque cardiaco congestivo PT831910E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48645695A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
PT831910E true PT831910E (pt) 2002-05-31

Family

ID=23931955

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96919170T PT831910E (pt) 1995-06-07 1996-06-05 Terapia de combinacao a base de um antagonista epoxi-esteroidal de aldosterona e um antagonista de angiotensina ii para o tratamento de ataque cardiaco congestivo

Country Status (21)

Country Link
US (1) US6653306B1 (cg-RX-API-DMAC7.html)
EP (1) EP0831910B1 (cg-RX-API-DMAC7.html)
JP (1) JPH11507627A (cg-RX-API-DMAC7.html)
KR (1) KR100618466B1 (cg-RX-API-DMAC7.html)
CN (2) CN1522701A (cg-RX-API-DMAC7.html)
AT (1) ATE209047T1 (cg-RX-API-DMAC7.html)
AU (1) AU725689B2 (cg-RX-API-DMAC7.html)
BR (1) BR9609066A (cg-RX-API-DMAC7.html)
CA (1) CA2224079A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ297975B6 (cg-RX-API-DMAC7.html)
DE (1) DE69617235T2 (cg-RX-API-DMAC7.html)
DK (1) DK0831910T3 (cg-RX-API-DMAC7.html)
ES (1) ES2167571T3 (cg-RX-API-DMAC7.html)
IL (1) IL122242A (cg-RX-API-DMAC7.html)
NO (1) NO318184B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ310730A (cg-RX-API-DMAC7.html)
PL (1) PL185150B1 (cg-RX-API-DMAC7.html)
PT (1) PT831910E (cg-RX-API-DMAC7.html)
RO (1) RO118046B1 (cg-RX-API-DMAC7.html)
RU (1) RU2166330C2 (cg-RX-API-DMAC7.html)
WO (1) WO1996040257A1 (cg-RX-API-DMAC7.html)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK92899A3 (en) * 1997-01-10 2000-08-14 Merck & Co Inc Use of angiotensin ii antagonists to treat symptomatic heart failure
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
IL145237A0 (en) * 1999-03-05 2002-06-30 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
WO2001087284A2 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
AU7804501A (en) * 2000-07-27 2002-02-13 Pharmacia Corp Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
ATE338566T1 (de) * 2000-07-27 2006-09-15 Pharmacia Corp Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US20050124624A1 (en) * 2002-03-15 2005-06-09 Gilbert Richard E. 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for threating ang ii-mediated diseases
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
US20070123498A1 (en) * 2003-10-17 2007-05-31 Shetty Suraj S Combination of organic compounds
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
CN101024643A (zh) * 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
MX2010007419A (es) * 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
EP2358720B1 (en) 2008-10-16 2016-03-02 The Regents of The University of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CN102369205B (zh) 2009-01-30 2014-10-29 武田药品工业株式会社 稠环化合物和其用途
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
ES2984389T3 (es) 2016-06-29 2024-10-29 Univ Montreal Heterociclos de biarilmetilo
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EA202191152A1 (ru) 2018-10-29 2022-01-19 Миокардиа, Инк. Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11971205B2 (en) 2021-08-20 2024-04-30 Pioneer Family Brands, Inc. Ice shaver with splash guard
US11982483B2 (en) 2021-08-20 2024-05-14 Pioneer Family Brands, Inc. Ice shaver with multi-link control arm
US12044455B2 (en) 2021-08-20 2024-07-23 Pioneer Family Brands, Inc. Ice shaver with thermally isolated shave deck

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
CA2109524A1 (en) * 1991-05-10 1992-11-11 Prasun K. Chakravarty Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US6008210A (en) * 1992-04-21 1999-12-28 Weber; Karl T. Use of aldosterone antagonists to inhibit myocardial fibrosis
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
AU5449194A (en) * 1992-10-26 1994-05-24 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases

Also Published As

Publication number Publication date
AU6157796A (en) 1996-12-30
ES2167571T3 (es) 2002-05-16
JPH11507627A (ja) 1999-07-06
CZ297975B6 (cs) 2007-05-09
ATE209047T1 (de) 2001-12-15
CN1142793C (zh) 2004-03-24
DK0831910T3 (da) 2002-05-21
IL122242A (en) 2001-07-24
EP0831910B1 (en) 2001-11-21
KR100618466B1 (ko) 2006-12-13
NO975741D0 (no) 1997-12-05
NO318184B1 (no) 2005-02-14
PL185150B1 (pl) 2003-03-31
WO1996040257A1 (en) 1996-12-19
EP0831910A1 (en) 1998-04-01
NO975741L (no) 1998-01-29
US6653306B1 (en) 2003-11-25
DE69617235T2 (de) 2002-07-25
AU725689B2 (en) 2000-10-19
BR9609066A (pt) 1999-01-26
CZ385097A3 (cs) 1998-06-17
NZ310730A (en) 2001-01-26
IL122242A0 (en) 1998-04-05
CA2224079A1 (en) 1996-12-19
RU2166330C2 (ru) 2001-05-10
RO118046B1 (ro) 2003-01-30
PL324001A1 (en) 1998-04-27
KR19990022548A (ko) 1999-03-25
DE69617235D1 (de) 2002-01-03
CN1192697A (zh) 1998-09-09
CN1522701A (zh) 2004-08-25

Similar Documents

Publication Publication Date Title
PT831910E (pt) Terapia de combinacao a base de um antagonista epoxi-esteroidal de aldosterona e um antagonista de angiotensina ii para o tratamento de ataque cardiaco congestivo
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
FI974173A0 (fi) Endoteliiniantagonisteja ja endoteliinisyntaasi-inhibiittoreita kohdunsupistussairauksien, raskausmyrkytyksen esivaiheen, valtimon haurausk ovetustaudin ja verenpainetaudin ennaltaehkäisemiseksi ja hoitamiseksi sekä hormonipalautusterapiaan
WO1997036609A3 (en) Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest
DE69814394D1 (de) Verwendung von levobupivacain
DE69733654D1 (de) Anwendung von thermotherapie
BR9805544C1 (pt) Uso de um composto.
ITSV970008V0 (it) Apparecchio ortodontico per l'espansione e la contrazione ortodontica e ortopedica del mascellare superiore.
EP0726072A3 (en) Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
AU8534291A (en) Renal-selective angiotensin ii antagonists for treatment of hypertension
DE69835288D1 (de) Kombinationstherapie zur modulation der humanen sexualreaktion
ATE543451T1 (de) Bioabsorbierbare, osteogenetische knochenplatte
NO984432L (no) FremgangsmÕte for behandling av migrenesmerte
AU4726797A (en) Prophylactic/remedial agent
EE9900010A (et) T-BAM (CD40L) tehnoloogia terapeutilised rakendused silelihasrakkudega seotud haiguste ravimiseks
NO20001548L (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat
ID24922A (id) Terapi kombinasi untuk pengobatan aids
BG103859A (en) The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions
NO955056L (no) Enantiomerer av 4-(5-fluor-2,3-dihydro-1H-inden-2-yl)-1H-imidazol
BR9607612A (pt) Terapia de combinaç o de inibidor de enzima de conversão de angiotensina quantidade de reduzido efeito colateral de antagonista da aldosterona e diurético par tratamento de doenças cardiovasculares
ITTO940226A0 (it) Piastra elettrodica per l'elettrostimolazione transcutanea localizzatadi tessuti.
UA10257A (uk) Спосіб фізіотерапевтичного впливу на організм людини
MX9706424A (es) Uso de la moxonidina para el tratamiento de la aterosclerosis.